Life Medical Sciences Inc , warum läuft CHAI nicht mit FDAzulassung - 500 Beiträge pro Seite

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/16/2003 (09:29 ET) New 3/A just released for CHAI - Edgar



07/15/2003 (17:19 ET) New 3 just released for CHAI - Edgar



07/15/2003 (16:00 ET) New 3 just released for CHAI - Edgar



07/08/2003 (09:20 ET) PREMARKET: CHAI Receives $800,000 Financing - Knobias



07/08/2003 (07:30 ET) Life Medical Sciences Receives $800,000 Financing - PR Newswire

[js200]

@MORCHEL

Ich habe mir erlaubt deine Aktie hier vorzustellen

JS200

[js200]

Life Medical Sciences Receives $800,000 Financing

Tuesday , July 08, 2003 07:30 ET

OCEANPORT, N.J., Jul 8, 2003 /PRNewswire-FirstCall via COMTEX/ -- Life Medical Sciences, Inc. (OTC Bulletin Board: CHAI), today announced that it has received approximately $800,000 in new financing through the exercise of warrants to purchase the Company`s common shares. The warrants were otherwise scheduled to expire on June 30, 2003. "We are gratified that 100% of these outstanding warrants were exercised" stated Robert P. Hickey, President & CEO of Life Medical Sciences, "The proceeds will support the funding of the pivotal clinical trial for our REPEL-CV(TM) cardiac adhesion barrier product, the next major step in our plan to become a viable competitor in the estimated $2.0 billion adhesion prevention therapy market". The Company has received approval from the Food and Drug Administration (FDA) for the pivotal clinical trial and it plans to begin patient enrollment in the near future.

The warrants were issued as part of a private placement of 604,000 Units at $1.20 per Unit that closed in March/April 2003. Each Unit consisted of one share of Series C Convertible Preferred Stock; one warrant entitling the holder to purchase, until June 30, 2003, ten shares of Common Stock at $0.12 per share; and one two-year warrant entitling the holder to purchase ten shares of Common Stock at $0.12 per share. Each share of preferred stock automatically converts into ten shares of Common Stock at the end of March 2004. Clubb BioCapital, Ltd. of London acted as the Company`s agent in the private placement. Proceeds from the warrant exercise includes funds from the exercise of warrants issued as compensation to the agent.

Life Medical Sciences, Inc. is a biomaterials company engaged in the development and commercialization of innovative and cost-effective medical devices. The Company is developing a broad range of bioresorbable polymer products to prevent/reduce post-operative adhesion formation.

Certain statements in this Press Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Reference is made to the Company`s Annual Report on Form 10-KSB for the year ended December 31, 2002 for a description of some of these risks and uncertainties.

SOURCE Life Medical Sciences, Inc.


CONTACT: Robert P. Hickey of Life Medical Sciences, Inc.,
[phone], [e-mail]
(CHAI)

http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: New Jersey
INDUSTRY KEYWORD: BIO
HEA
MTC
SUBJECT CODE: FNC


STOCK SYMBOLS: [(chai)]

JS200

[js200]

Sehr heisses EISEN

Last Trade: 0.510 Change: 0.000 ( +0.000 %)



Previous Close: 0.510 Today`s Open: 0.510



# of Trades: 2 Volume: 1,500



Avg. # of Trades: 6 Avg. Daily Volume: 13,870





Bid: 0.490 Bid Size: 50



Ask: 0.570 Ask Size: 25



Day High: 0.510 Day Low: 0.510



52 Week High: 0.700 52 Week Low: 0.050



Market Cap: 17.75M Dividend: N/A



EPS: -0.11 P/E Ratio: N/A

[js200]

http://www.lifemedicalsciences.com/

JS200

[morchel]

ist schon gut!

Der Grund warum CHAI noch nicht sooo läuft ist das die FDA jetzt die Zulassung gegeben hat für Tests die sich über 18 Monate hinziehen werden1

Werde noch genauer nachforschen wie es mit den anderen Produkten aussieht!

morchel

[2 PAC]

clinical-trial-zulassung? wow, heute ist wieder ein sack reis in china umgefallen!

18 monate, richtig Morchel, und danach kommen noch weitere phasen - bis zum final-fda-approval dauert es meistens ca 5 jahre! die meisten firmen schaffen es jedoch nicht, von einer otc-bude kann man dies erst recht nicht verlangen!

2 PAC

[morchel]

wkn: 885859

2PAC...du hast 0 Ahnung!

Es handelt sich hier um kein Medikament und das ist ausschlaggebend! Und noch viel wichtiger: Es gibt kein vergleichbares Produkt: There are no FDA approved products currently available to the cardiovascular surgeon to address post-operative adhesion formation.

Wärs ein Medikament würde ich sagen NO!

Aber so:
The trend is your friend:


Consultants and Advisors
Daniel Cohn, Ph.D.
Professor of Biomaterials Science and Head of the Biomedical
Polymers Research Group, Casali Institute of Applied Chemistry,
Hebrew University, Jerusalem, Israel
Michael P. Diamond, M.D.
Professor of Obstetrics and Gynecology at Wayne State
University in Detroit, Michigan, and Director of the Division of
Reproductive Endocrinology and Infertility
Gere S. diZerega, M.D.
Professor, Department of Obstetrics and Gynecology at
Womens` Hospital, University of Southern California Medical Center
Steven R. Gundry, M. D.
Director of the International Heart Institute
at the Dessert Regional Medical Center, Palm Springs, CA
and Professor, Departments of Surgery and Pediatrics at
Loma Linda University School of Medicine
Mehmet C. Oz, M.D.
Assistant Professor of Surgery at Columbia University College
of Physicians and Surgeons, New York and Director of The Assist
Device Program and attending surgeon of the Division of Cardiothoracic Surgery at New York-Presbyterian Medical Center, New York
Eric A. Rose, M.D.
Chairman, Department of Surgery at College of
Physicians & Surgeons of Columbia University, New York,
Surgeon-in-Chief of New York-Presbyterian Medical Center,
New York and Director, Cardio-Thoracic Services at St. Michael`s
Medical Center, Newark, New Jersey
Samuel Weinstein, M.D.
Assistant Professor of Surgery, Division of Pediatric Cardiothoracic
Surgery, Children`s Hospital at The Ohio State University Medical
Center

Directors
RICHARD L. FRANKLIN, MD
Chairman of the Board
Chairman
DMS Data Systems

DAVID G. P. ALLAN
Chairman & CEO
YM Biosciences Inc.

EDWARD A. CELANO
Managing Director
M.R. Weiser & Co., LLP

BARRY R. FRANKEL
Managing Partner
The Frankel Group



ROBERT P. HICKEY
President & CEO
WALTER R. MAUPAY, JR.
Retired Group Executive
Bristol-Myers Squibb

IRWIN M. ROSENTHAL
Partner
Duane Morris, LLP


morchel

[js200]

@ 2 PAC



JS200